BGMS Bio Green Med Solution, Inc. - Common Stock
$0,91
Preço · Ago 18, 2026
Fundamentais a partir de Ago 14, 2026
Intervalo 52 Semanas
$1–$9
4% of range
Classificação do Analista
HOLD
6 analysts
Preço-Alvo
—
P/E (TTM)
-0.1
ROE
-57.2%
Margem de Lucro Líquido
—
Sobre Bio Green Med Solution, Inc. - Common Stock Visão geral da empresa da Wikipedia
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow.
Ler mais
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow.
Company overview
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.
Three product candidates are currently in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analogue, failed its Phase 3 trial for the treatment of acute myeloid leukemia (AML) in the elderly. Phase 1/2 studies are ongoing for the treatment of breast cancer and AML/MDS. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors.
Cyclacel Pharmaceuticals' ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia.
Reverse merger
After becoming the first European spin-out company to raise over $100 million in private equity, the company had to pull out of a stock market listing in July 2004. Cyclacel completed a reverse merger with Xcyte Therapies in December 2005 to acquire Nasdaq listing. This allowed Cyclacel to raise an additional $45 million in April 2006 through a private placement of stock and warrants.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
BGMS Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$0.91
Capitalização de Mercado
$5M
P/E (TTM)
-0.1
EPS (TTM)
$-6.45
Receita (TTM)
$0
Rendimento div.
—
ROE
-57.2%
Dívida/Capital
—
Intervalo 52 Semanas
$1 – $9
BGMS Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$0
2021-12-31
→
2025-12-31
EPS
$-6.45
2021-12-31
→
2025-12-31
Fluxo de caixa livre
—
2021-12-31
→
2022-12-31
Margens
—
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
BGMS
Mediana de Pares
P/E (TTM)
-0.1
—
P/B
0.7
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
BGMS
Mediana de Pares
ROA
-48.8%
-106.7%
ROE
-57.2%
-51.9%
ROIC
-123.4%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
BGMS
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
4.7
3.3
Quick Ratio (Índice de Liquidez Seca)
3.6
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
BGMS
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
-89.8%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
BGMS
Mediana de Pares
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
Dividend Yield
—
Índice de Pagamento
—
CAGR Dividendos 5 anos
—
| Data ex | Valor |
|---|---|
| 29 de Abril de 2025 | $36,0000 |
BGMS Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
VENDA
6 analistas
- Compra forte 0 0,0%
- Compra 0 0,0%
- Manter 3 50,0%
- Venda 1 16,7%
- Venda forte 2 33,3%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
208.9%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Setembro de 2024 | $-43.20 | $-135.86 | 92.7% |
| 30 de Junho de 2024 | $-172.80 | $-351.29 | 178.5% |
| 31 de Março de 2024 | $-544.80 | $-1161.58 | 616.8% |
| 31 de Dezembro de 2023 | $-1495.20 | $-1442.69 | -52.5% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| BGMS | $8M | -0.2 | -89.8% | — | -57.2% | — |
| ALPS | — | — | — | — | — | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $43.0K | $420.0K | $0 | $0 | $0 | · | $150.0K | · | · | · | · | |
| R&D Expense | $848.0K | $7M | $19M | $20M | $15M | $5M | $5M | $4M | · | · | · | · | |
| SG&A Expense | $8M | $5M | $7M | $7M | $7M | $6M | $5M | $5M | · | · | · | · | |
| Operating Expenses | $9M | $12M | $26M | $28M | $22M | $11M | $10M | $10M | · | · | · | · | |
| Operating Income | $-8M | $-12M | $-25M | $-28M | $-22M | $-11M | $-10M | $-10M | · | · | · | · | |
| Interest Income | · | $12.0K | $266.0K | $210.0K | $16.0K | $42.0K | $224.0K | $331.0K | · | · | · | · | |
| Other Non-op | $354.0K | $52.0K | $50.0K | $1M | $204.0K | $955.0K | $556.0K | $923.0K | · | · | · | · | |
| Pretax Income | $-3M | $-12M | $-26M | $-26M | $-22M | $-10M | $-9M | $-9M | · | · | · | · | |
| Income Tax | $7.0K | $-782.0K | $-3M | $-5M | $-4M | $-1M | $-1M | $-1M | · | · | · | · | |
| Net Income | $-3M | $-11M | $-23M | $-21M | $-18M | $-8M | $-8M | $-7M | · | · | · | · | |
| EPS (Basic) | $-6.45 | $-502.46 | $-6419.18 | $-1.90 | $-2.09 | $-3.42 | · | · | · | · | · | · | |
| EPS (Diluted) | $-6.45 | $-502.46 | $-6419.18 | $-27.24 | $-2.09 | $-3.42 | · | · | · | · | · | · | |
| Shares (Basic) | 2,185,075 | 22,314 | 3,545,000 | 11,255,677 | 8,926,173 | 3,633,385 | · | · | · | · | · | · | |
| Shares (Diluted) | 2,185,075 | 22,314 | 3,545,000 | 11,255,677 | 8,926,173 | 3,633,385 | · | · | · | · | · | · | |
| EBITDA | $-8M | $-12M | · | $-28M | $-23M | $-11M | $-10M | · | · | · | · | · |
Balanço Patrimonial 25
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $3M | $3M | $18M | $37M | $33M | $12M | $18M | · | · | · | · | |
| Short-term Investments | · | · | · | $5M | $4M | $5M | $11M | $17M | · | · | · | · | |
| Receivables | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $110.0K | $537.0K | $4M | $6M | $4M | $2M | $2M | $2M | · | · | · | · | |
| Other Current Assets | · | $300.0K | $341.0K | $426.0K | $79.0K | $66.0K | $103.0K | $236.0K | · | · | · | · | |
| Current Assets | $6M | $4M | $7M | $24M | $41M | $35M | $14M | $20M | · | · | · | · | |
| PP&E (Net) | $137.0K | $3.0K | $9.0K | $32.0K | $64.0K | $106.0K | $27.0K | $36.0K | · | · | · | · | |
| PP&E (Gross) | $421.0K | $427.0K | $429.0K | $415.0K | $425.0K | $991.0K | $6M | $6M | · | · | · | · | |
| Accum. Depreciation | $284.0K | $424.0K | $420.0K | $383.0K | $361.0K | $886.0K | $6M | $6M | · | · | · | · | |
| Goodwill | $2M | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $8M | $4M | $9M | $28M | $43M | $37M | $15M | $20M | · | · | · | · | |
| Accounts Payable | $617.0K | $5M | $4M | $3M | $2M | $514.0K | $890.0K | $3M | · | · | · | · | |
| Accrued Liabilities | $715.0K | $2M | $5M | $5M | $3M | $2M | $2M | $2M | · | · | · | · | |
| Current Liabilities | $1M | $6M | $8M | $8M | $5M | $2M | $2M | $4M | · | · | · | · | |
| Capital Leases | $2.0K | · | $37.0K | $106.0K | $30.0K | $1M | $1M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Total Liabilities | $1M | $6M | $8M | $8M | $5M | $4M | $4M | $5M | · | · | · | · | |
| Common Stock | $5.0K | · | · | $1.0K | $10.0K | $6.0K | $1.0K | $12.0K | · | · | · | · | |
| Paid-in Capital | $461M | $438M | $430M | $423M | $423M | $400M | $370M | $366M | · | · | · | · | |
| Retained Earnings | $-454M | $-439M | $-428M | $-406M | $-385M | $-366M | $-358M | $-350M | · | · | · | · | |
| AOCI | $-39.0K | $-891.0K | $-908.0K | $-1M | $-748.0K | $-746.0K | $-819.0K | $-760.0K | · | · | · | · | |
| Stockholders' Equity | $7M | $-2M | $607.0K | $16M | $38M | $33M | $12M | $15M | $22M | · | · | · | |
| Liabilities + Equity | $8M | $4M | $9M | $28M | $43M | $37M | $15M | $20M | · | · | · | · | |
| Shares Outstanding | 5,400,320 | 36,913 | 4,412 | 628,139 | 9,993,135 | 6,246,896 | 859,998 | 12,497,447 | · | · | · | · |
Fluxo de Caixa 12
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | $20.0K | $20.0K | $29.0K | · | · | · | · | |
| Stock-based Comp | $2M | $592.0K | $1M | $2M | $1M | $430.0K | $466.0K | $331.0K | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $61.0K | $-2M | · | · | · | · | · | |
| Operating Cash Flow | $-5M | $-8M | $-16M | $-21M | $-19M | $-8M | $-9M | $-7M | · | · | · | · | |
| CapEx | · | · | $6.0K | $7.0K | $27.0K | $96.0K | $10.0K | $39.0K | · | · | · | · | |
| Investing Cash Flow | · | · | $-6.0K | $-7.0K | $-27.0K | $-96.0K | $28.0K | $-39.0K | · | · | · | · | |
| Stock Issued | · | · | · | · | $4M | $30M | $4M | $630.0K | · | · | · | · | |
| Net Stock Activity | · | · | · | · | $4M | $30M | $4M | · | · | · | · | · | |
| Financing Cash Flow | $5M | $8M | $848.0K | $3M | $22M | $30M | $4M | $429.0K | · | · | · | · | |
| Net Change in Cash | $368.0K | $-241.0K | $-15M | $-18M | $3M | $22M | $-6M | $-6M | · | · | · | · | |
| Taxes Paid | $18.0K | $2.0K | $2.0K | $2.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | $-21M | $-19M | $-8M | $-9M | · | · | · | · | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -27916.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | · | -26074.4% | · | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | · | -27893.0% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | -27916.3% | · | · | · | · | · | · | · | · | · | · | |
| ROA | -48.8% | -173.8% | · | · | -43.0% | -32.4% | -44.6% | · | · | · | · | · | |
| ROE | -57.2% | 713.2% | · | · | -47.9% | -29.3% | -61.3% | · | · | · | · | · | |
| ROIC | -123.4% | 516.2% | · | · | -51.1% | -27.9% | -71.0% | · | · | · | · | · |
Liquidez e Solvência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 0.6 | · | · | 7.7 | 14.3 | 5.8 | · | · | · | · | · | |
| Quick Ratio | 3.6 | 0.5 | · | · | 7.8 | 15.6 | 9.5 | · | · | · | · | · |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | · | 0.0 | · | · | · | · | · | · | · | |
| Receivables Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · |
Taxas de Crescimento 1
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | -89.8% | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $43.0K | $420.0K | $0 | $0 | $0 | $823.0K | $150.0K | $823.0K | $823.0K | $823.0K | $823.0K | |
| Net Income TTM | $-3M | $-11M | $-23M | $-21M | $-18M | $-8M | $-8M | $-7M | $-8M | $-8M | $-8M | $-8M | |
| Market Cap | $8M | $3M | · | · | $139.94B | $175.64B | $829.73B | · | · | · | · | · | |
| P/E | -0.2 | -0.2 | -0.1 | -88.5 | -6700.5 | -8221.1 | · | · | · | · | · | · | |
| P/S | · | 78.3 | · | · | · | · | 1008173.4 | · | · | · | · | · | |
| P/B | 1.2 | -1.5 | · | · | 3755.6 | 5280.9 | 70935.0 | · | · | · | · | · | |
| P / Tangible Book | 1.5 | · | 1117.9 | 1897.5 | 3712.7 | 5280.9 | · | · | · | · | · | · | |
| P / Cash Flow | -1.7 | -0.4 | · | · | -7548.2 | -22137.3 | -87829.7 | · | · | · | · | · | |
| P / FCF | · | · | · | · | -7537.2 | -21872.7 | -87736.8 | · | · | · | · | · | |
| Earnings Yield | -435.8% | -550.9% | -1001.7% | -1.1% | -0.01% | -0.01% | · | · | · | · | · | · |
Demonstração de Resultados 15
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $357.0K | $743.0K | $-81.0K | $81.0K | · | · | $0 | $10.0K | $4.0K | $29.0K | $31.0K | $16.0K | $373.0K | $0 | $0 | $0 | |
| R&D Expense | · | · | $-47.0K | $5.0K | $68.0K | $822.0K | $880.0K | $950.0K | $2M | $3M | $4M | $5M | $5M | $6M | $7M | $4M | |
| SG&A Expense | $497.0K | $389.0K | $1M | $1M | $1M | $4M | $948.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Expenses | $754.0K | $1M | $2M | $1M | $1M | $4M | $2M | $2M | $4M | $4M | $5M | $7M | $6M | $7M | $9M | $6M | |
| Operating Income | $-418.0K | $-246.0K | $-1M | $-992.0K | $-1M | $-4M | $-2M | $-2M | $-4M | $-4M | $-5M | $-7M | $-6M | $-7M | $-9M | $-6M | |
| Interest Income | · | · | · | · | · | · | · | · | · | $2.0K | $23.0K | $50.0K | $77.0K | $116.0K | $122.0K | $67.0K | |
| Other Non-op | $31.0K | $31.0K | $333.0K | $9.0K | $2.0K | $10.0K | $0 | · | · | $52.0K | $-1.0K | $-9.0K | $-106.0K | $166.0K | $-255.0K | $14.0K | |
| Pretax Income | $-396.0K | $-167.0K | $-606.0K | $-988.0K | $-1M | $-4M | $-2M | $-2M | $-4M | $-4M | $-6M | $-7M | $-6M | $-7M | $-9M | $-6M | |
| Income Tax | $9.0K | $30.0K | $5.0K | · | $2.0K | · | $1M | $-210.0K | $-412.0K | $-1M | $-422.0K | $-668.0K | $-586.0K | $-1M | $-2M | $-1M | |
| Net Income | $-405.0K | $-197.0K | $-611.0K | $-988.0K | $-1M | $-81.0K | $-3M | $-2M | $-3M | $-3M | $-5M | $-6M | $-5M | $-6M | $-7M | $-5M | |
| EPS (Basic) | · | · | $-4.16 | $-1.31 | $-0.98 | $0.00 | $-284.21 | $-43.80 | $-172.18 | $-2.27 | · | · | $-0.44 | $-0.47 | · | $-0.42 | |
| EPS (Diluted) | · | · | $-4.16 | $-1.31 | $-0.98 | $0.00 | $-284.21 | $-43.80 | $-172.18 | $-2.27 | · | · | $-0.44 | $-7.00 | $-25.94 | $-0.42 | |
| Shares (Basic) | 5,598,701 | 5,458,564 | 816,121 | 1,912,495 | 1,360,626 | 365,231 | 5,668 | 44,681 | · | · | · | · | 12,551,794 | 12,539,189 | · | 12,314,679 | |
| Shares (Diluted) | 5,598,701 | 5,458,564 | 816,121 | 1,912,495 | 1,360,626 | 365,231 | 5,668 | 44,681 | · | · | · | · | 12,551,794 | 12,539,189 | · | 12,314,679 | |
| EBITDA | $-418.0K | $-246.0K | · | $-992.0K | $-1M | $-5M | · | $-2M | $-4M | $-4M | · | $-7M | $-6M | $-7M | · | $-6M |
Balanço Patrimonial 23
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $6M | $3M | $3M | $6M | $10M | $11M | $18M | $24M | |
| Receivables | $1M | $1M | $1M | $725.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $972.0K | $947.0K | $1M | $1M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $133.0K | $148.0K | $110.0K | $513.0K | $108.0K | $264.0K | $537.0K | $2M | $2M | $2M | $4M | $5M | $5M | $8M | $6M | $4M | |
| Other Current Assets | · | · | · | $460.0K | $58.0K | $194.0K | · | $309.0K | $300.0K | $365.0K | $341.0K | $2M | $2M | $595.0K | $426.0K | $170.0K | |
| Current Assets | $6M | $6M | $6M | $6M | $4M | $4M | $4M | $5M | $8M | $5M | $7M | $11M | $15M | $19M | $24M | $28M | |
| PP&E (Net) | $136.0K | $138.0K | $137.0K | $129.0K | $1.0K | $1.0K | $3.0K | $4.0K | $5.0K | $7.0K | $9.0K | $16.0K | $24.0K | $31.0K | $32.0K | $37.0K | |
| PP&E (Gross) | · | · | $421.0K | · | · | · | $427.0K | · | · | · | $429.0K | · | · | · | $415.0K | · | |
| Accum. Depreciation | · | · | $284.0K | · | · | · | $424.0K | · | · | · | $420.0K | · | · | · | $383.0K | · | |
| Goodwill | $2M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $8M | $8M | $8M | $8M | $4M | $4M | $4M | $5M | $8M | $6M | $9M | $12M | $16M | $22M | $28M | $31M | |
| Accounts Payable | $189.0K | $256.0K | $617.0K | $468.0K | $221.0K | $114.0K | $5M | $4M | $5M | $5M | $4M | $2M | $2M | $3M | $3M | $983.0K | |
| Accrued Liabilities | $503.0K | $540.0K | $715.0K | $534.0K | $539.0K | $549.0K | $2M | $2M | $2M | $3M | $5M | $7M | $5M | $5M | $5M | $3M | |
| Current Liabilities | $692.0K | $796.0K | $1M | $1M | $760.0K | $663.0K | $6M | $6M | $7M | $8M | $8M | $8M | $7M | $7M | $8M | $4M | |
| Capital Leases | · | · | $2.0K | $5.0K | $10.0K | $9.0K | · | $0 | $5.0K | $21.0K | $37.0K | $52.0K | $66.0K | $80.0K | $106.0K | $107.0K | |
| Total Liabilities | $694.0K | $804.0K | $1M | $1M | $770.0K | $672.0K | $6M | $6M | $7M | $8M | $8M | $8M | $7M | $7M | $8M | $4M | |
| Common Stock | $7.0K | $5.0K | $5.0K | $3.0K | $2.0K | $204.0K | · | $2.0K | $2.0K | $1.0K | · | $12.0K | $9.0K | $9.0K | $1.0K | $9.0K | |
| Paid-in Capital | $462M | $461M | $461M | $451M | $445M | $443M | $438M | $437M | $436M | $430M | $430M | $428M | $424M | $423M | $423M | $423M | |
| Retained Earnings | $-455M | $-455M | $-454M | $-444M | $-442M | $-440M | $-439M | $-436M | $-434M | $-431M | $-428M | $-423M | $-417M | $-412M | $-406M | $-399M | |
| AOCI | · | $-30.0K | $-39.0K | · | · | · | $-891.0K | $-1M | $-915.0K | $-898.0K | $-908.0K | $-1M | $-1M | $-1M | $-1M | $-2M | |
| Stockholders' Equity | $7M | $7M | $7M | $7M | $4M | $3M | $-2M | $-970.0K | $999.0K | $-2M | $607.0K | $4M | $5M | $10M | $16M | $22M | |
| Liabilities + Equity | $8M | $8M | $8M | $8M | $4M | $4M | $4M | $5M | $8M | $6M | $9M | $12M | $16M | $22M | $28M | $31M | |
| Shares Outstanding | 6,622,794 | 5,519,456 | 5,400,320 | 3,497,537 | 1,583,965 | 207,336,389 | 36,913 | 2,152,202 | 1,805,204 | 1,318,259 | 4,412 | 12,642,822 | 12,642,822 | 12,539,189 | 628,139 | 12,539,189 |
Fluxo de Caixa 8
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $0 | $1.0K | $655.0K | $6.0K | $7.0K | $2M | $93.0K | $107.0K | $189.0K | $203.0K | $322.0K | $391.0K | $359.0K | $401.0K | $387.0K | $389.0K | |
| Operating Cash Flow | $-352.0K | $-278.0K | $-33.0K | $-434.0K | $-1M | $-3M | $-1M | $-3M | $-3M | $-483.0K | $-4M | $-4M | $-1M | $-7M | $-5M | $-7M | |
| CapEx | $0 | $1.0K | · | · | · | · | · | $0 | · | · | $0 | $0 | $0 | $6.0K | $0 | $0 | |
| Investing Cash Flow | $0 | $-1.0K | · | · | · | · | · | $0 | · | · | $0 | $0 | $0 | $-6.0K | $0 | $0 | |
| Financing Cash Flow | $773.0K | $105.0K | $-259.0K | $-3.0K | $2M | $4M | $2M | $-1.0K | $6M | $-79.0K | $999.0K | $-50.0K | $-51.0K | $-50.0K | $42.0K | $2M | |
| Net Change in Cash | $451.0K | $-166.0K | $-333.0K | $-437.0K | $825.0K | $313.0K | $155.0K | $-3M | $3M | $-580.0K | $-3M | $-4M | $-1M | $-7M | $-5M | $-5M | |
| Taxes Paid | · | · | · | · | · | · | $0 | $0 | $0 | $2.0K | $0 | $0 | $0 | $2.0K | $0 | $0 | |
| Free Cash Flow | · | $-279.0K | · | · | · | · | · | · | · | · | · | · | · | $-7M | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -4644.4% | -33.1% | · | -1224.7% | -65850.0% | -83933.3% | · | -21770.0% | -91100.0% | -15017.2% | · | -42781.2% | -1589.5% | · | · | · | |
| Net Margin | -4500.0% | -26.5% | · | -1219.8% | -65900.0% | -1350.0% | · | -19570.0% | -81425.0% | -10158.6% | · | -37700.0% | -1460.6% | · | · | · | |
| Pretax Margin | -4400.0% | -22.5% | · | -1219.8% | -65800.0% | -1350.0% | · | -21670.0% | -91725.0% | -14827.6% | · | -41875.0% | -1617.7% | · | · | · | |
| EBITDA Margin | -4644.4% | -33.1% | · | -1224.7% | -65850.0% | -83933.3% | · | -21770.0% | -91100.0% | -15017.2% | · | -42781.2% | -1589.5% | · | · | · | |
| ROA | -6.6% | -3.5% | · | -14.6% | -20.9% | -1.6% | · | -21.9% | -26.5% | -20.9% | · | -27.7% | -21.0% | -18.8% | · | -13.4% | |
| ROE | -7.5% | -4.0% | · | -32.3% | -56.9% | -18.9% | · | -117.6% | -106.2% | -74.2% | · | -45.8% | -30.8% | -26.7% | · | -16.1% | |
| ROIC | -6.0% | -4.3% | · | · | -36.3% | · | · | 202.7% | -323.8% | 135.2% | · | -143.4% | -104.2% | -58.8% | · | -24.4% |
Liquidez e Solvência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.6 | 7.1 | · | 6.4 | 5.8 | 5.6 | · | 0.8 | 1.1 | 0.6 | · | 1.4 | 2.3 | 2.6 | · | 6.4 | |
| Quick Ratio | 7.0 | 5.7 | · | 4.6 | 5.6 | 5.2 | · | 0.5 | 0.8 | 0.3 | · | 0.7 | 1.5 | 1.6 | · | 5.4 |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 0.0 | 1.3 | · | 0.2 | · | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | $59.0K | $59.0K | · | $59.0K | $422.0K | $418.0K | · | $389.0K | $373.0K | $0 | · | $0 | |
| Net Income TTM | $-3M | $-3M | · | $-4M | $-7M | $-8M | · | $-14M | $-18M | $-20M | · | $-22M | $-21M | $-20M | · | $-19M | |
| Market Cap | $6M | $6M | · | $17M | $8M | $13.93B | · | $511M | $702M | $668M | · | $15.93B | $26.85B | $25.73B | · | $65.91B | |
| P/E | -0.0 | -0.0 | · | -0.1 | -0.0 | -0.3 | · | · | · | · | · | -151.4 | -255.3 | -247.2 | · | -2903.9 | |
| P/S | · | · | · | · | 132.9 | 236152.6 | · | 8667.2 | 1663.2 | 1597.0 | · | 40951.0 | 71992.9 | · | · | · | |
| P/B | 0.8 | 0.8 | · | 2.4 | 2.2 | 4550.3 | · | -527.2 | 702.6 | -302.6 | · | 3707.2 | 5228.5 | 2535.5 | · | 2986.6 | |
| P / Tangible Book | 1.1 | 1.1 | · | 3.1 | 2.2 | 4550.3 | · | · | 702.6 | · | · | 3707.2 | 5228.5 | 2535.5 | · | 2986.6 | |
| P / Cash Flow | · | -19.9 | · | · | · | -4291.0 | · | · | · | -1382.1 | · | · | · | -3750.2 | · | · | |
| P / FCF | · | -19.8 | · | · | · | · | · | · | · | · | · | · | · | -3747.0 | · | · | |
| Earnings Yield | -5064.8% | -4609.0% | · | -933.0% | -4383.0% | -324.8% | · | · | · | · | · | -0.66% | -0.39% | -0.40% | · | -0.03% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2023-03-31 | |
|---|---|---|---|---|---|
| Receita | $0 | $43.0K | $420.0K | — | — |
| Margem Operacional % | — | -27916.3% | — | — | — |
| Lucro líquido | $-3M | $-11M | $-23M | — | — |
| EPS Diluído | $-6.45 | $-502.46 | $-6419.18 | — | — |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2023-03-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 4.7 | 0.6 | — | — | — |
| Índice de Liquidez Seca | 3.6 | 0.5 | — | — | — |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 7 declarantes · $89K total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 1 (-2 vs trimestre anterior) | 3 (+1 vs trimestre anterior) | 4 (0 vs trimestre anterior) | 0 (0 vs trimestre anterior) | -21K |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | $68.468 | 75.240 | 76,95% | Ações |
| JANE STREET GROUP, LLC | $10.725 | 11.786 | 12,05% | Ações |
| Tower Research Capital LLC (TRC) | $5.207 | 5.722 | 5,85% | Ações |
| UBS Group AG | $3.942 | 4.332 | 4,43% | Ações |
| SBI Securities Co., Ltd. | $638 | 701 | 0,72% | Ações |
| Archer Investment Corp | $1 | 1 | 0,00% | Ações |
| OSAIC HOLDINGS, INC. | $0 | 1 | 0,00% | Ações |
Executivos da empresa 55 insiders · 18 diretores · 24 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Spiro George Rombotis | President and CEO | 21 de Dezembro de 2023 P | 68.658 | 0 | 0 | $0 |
| Ronald J Berenson | President and CEO | 3 de Fevereiro de 2005 A | 430.939 | 0 | 0 | $0 |
| Paul Mcbarron | E. VP, Fin, CFO, COO and Secretary | 21 de Dezembro de 2023 P | 33.378 | 0 | 0 | $0 |
| Stewart Craig | COO and VP | 3 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| Brian Schwartz | Interim Chief Medical Officer | 29 de Janeiro de 2024 A | 15.205 | 0 | 0 | $0 |
| Mark Kirschbaum | Chief Medical Officer | 30 de Junho de 2023 A | 31.200 | 0 | 0 | $0 |
| Judy Chiao | V.P., Clin. Dev. & Reg. Aff. | 5 de Dezembro de 2019 A | 39.024 | 0 | 0 | $0 |
| Robert Edward Sosnowski | VP, Marketing & Sales | 6 de Dezembro de 2011 A | 28.000 | 0 | 0 | $0 |
| William Collins | General Manager | 4 de Abril de 2008 A | — | 0 | 0 | $0 |
| Gregory Reyes | Senior VP, Research | 22 de Dezembro de 2007 A | 3.000 | 0 | 0 | $0 |
| Robert Westwood | V.P., Chem. & Preclin. Dev. | 21 de Dezembro de 2006 A | — | 0 | 0 | $0 |
| Robert Jackson | S.V.P. & Chief Scientific Offi | 14 de Junho de 2006 A | 64.841 | 0 | 0 | $0 |
| Lawrence A Romel | VP Clinical Operations | 3 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| Mark Frohlich | Medical Director and VP | 3 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| Joanna S Black | VP and General Counsel, Secret | 3 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| Kathi L Cordova | SVP Finance, Treasurer | 3 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| Mark L Bonyhadi | Vice President, Research | 3 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| Robert L Kirkman | Chief Business Officer and VP | 3 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| Avraham Ben-Tzvi | Conselheiro | 26 de Fevereiro de 2025 A | — | 0 | 0 | $0 |
| David Natan | Conselheiro | 26 de Fevereiro de 2025 A | 100.000 | 0 | 0 | $0 |
| Kenneth M. Ferguson | Conselheiro | 30 de Junho de 2023 A | 44.952 | 0 | 0 | $0 |
| Karin L Walker | Conselheiro | 30 de Junho de 2023 A | 40.602 | 0 | 0 | $0 |
| Robert J. Spiegel | Conselheiro | 30 de Junho de 2023 A | 39.415 | 0 | 0 | $0 |
| Christopher S Henney | Conselheiro | 30 de Junho de 2023 A | 39.415 | 0 | 0 | $0 |
| Sam L Barker | Conselheiro | 30 de Junho de 2023 A | 40.415 | 0 | 0 | $0 |
| Lloyd Sems | Conselheiro | 14 de Junho de 2022 A | 18.196 | 0 | 0 | $0 |
| Gregory T. Hradsky | Conselheiro | 15 de Junho de 2021 A | 2.374 | 0 | 0 | $0 |
| John Michael Middlecott Banham | Conselheiro | 25 de Junho de 2020 A | 36.847 | 0 | 0 | $0 |
| David C Uprichard | Conselheiro | 25 de Junho de 2020 A | 25.306 | 0 | 0 | $0 |
| Nicholas G Bacopoulos | Conselheiro | 22 de Maio de 2013 A | — | 0 | 0 | $0 |
| Daniel K Spiegelman | Conselheiro | 23 de Maio de 2012 A | — | 0 | 0 | $0 |
| Pierre Legault | Conselheiro | 19 de Fevereiro de 2008 A | — | 0 | 0 | $0 |
| John Gordon Mcvie | Conselheiro | 19 de Fevereiro de 2008 A | — | 0 | 0 | $0 |
| Peter Langecker | Conselheiro | 17 de Junho de 2005 A | 5.000 | 0 | 0 | $0 |
| Robert Michael Williams | Conselheiro | 17 de Junho de 2005 A | 45.700 | 0 | 0 | $0 |
| Robert Nelsen | Conselheiro | 17 de Junho de 2005 A | 2.054.271 | 0 | 0 | $0 |
| Stephen Wertheimer | Conselheiro | 17 de Junho de 2005 A | 574.363 | 0 | 0 | $0 |
| Robert E Curry | Conselheiro | 19 de Março de 2004 X | 960.964 | 0 | 0 | $0 |
| Lazar David E. | Detentor de 10% | 30 de Julho de 2025 S | 155.838 | 0 | 0 | $0 |
| MARXE AUSTIN W & GREENHOUSE DAVID M | Detentor de 10% | 23 de Setembro de 2011 S | 2.806.900 | 0 | 0 | $0 |
| MORGAN STANLEY | Detentor de 10% | 10 de Novembro de 2009 S | 2.276.852 | 0 | 0 | $0 |
| HEALTHCARE FOCUS FUND LP | Detentor de 10% | 29 de Outubro de 2004 P | 1.684.870 | 0 | 0 | $0 |
| Clinton Bybee | Detentor de 10% | 29 de Outubro de 2004 P | 2.054.271 | 0 | 0 | $0 |
| Keith Crandell | Detentor de 10% | 29 de Outubro de 2004 P | 2.054.271 | 0 | 0 | $0 |
| ARCH V ENTREPRENEURS FUND LP | Detentor de 10% | 29 de Outubro de 2004 P | 2.052.847 | 0 | 0 | $0 |
| ARCH VENTURE FUND V LP | Detentor de 10% | 29 de Outubro de 2004 P | 1.704.763 | 0 | 0 | $0 |
| Steven Lazarus | Detentor de 10% | 29 de Outubro de 2004 P | 2.054.271 | 0 | 0 | $0 |
| ARCH VENTURE FUND III L P | Detentor de 10% | 29 de Outubro de 2004 P | 913.784 | 0 | 0 | $0 |
| ARCH VENTURE FUND II LP | Detentor de 10% | 29 de Outubro de 2004 P | 1.860.824 | 0 | 0 | $0 |
| CREDIT SUISSE/ | Detentor de 10% | 19 de Março de 2004 X | 960.964 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 7 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Doris Wong Sing Ee ×2 declarações | 13 de Novembro de 2025 | 20,58% | Emenda | — | SEC |
| Lazar David E. ×3 declarações | 8 de Agosto de 2025 | 0,00% | Emenda | — | SEC |
| Tang Capital Partners, LP, Tang Capital Management, LLC, Kevin C. Tang ×3 declarações | 22 de Novembro de 2017 | — | Declaração inicial | — | SEC |
| EASTERN CAPITAL LIMITED, PORTFOLIO SERVICES LTD., KENNETH B. DART | 27 de Julho de 2017 | — | Declaração inicial | — | SEC |
| Austin W. Marxe and David M. Greenhouse ×3 declarações | 3 de Agosto de 2009 | — | Declaração inicial | Investimento passivo | SEC |
| 13 de Abril de 2006 | — | Declaração inicial | — | SEC | |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 12 de Novembro de 2004 | — | Declaração inicial | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.